Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals, Inc.
Your view on ANTH
Overview
What the company does, where it operates, and who runs it.
About Anthera Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul F. Truex
- Headquarters
- The Pennzoil Building, Houston, TX, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul F. Truex
- Headquarters
- The Pennzoil Building, Houston, TX, US
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.
It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.
The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Anthera Pharmaceuticals, Inc., and the rating behind it. ANTH last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Anthera Pharmaceuticals, Inc.. Starting points for Anthera Pharmaceuticals, Inc.: EPS -$1.65, beta -123.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Anthera Pharmaceuticals, Inc.. Anthera Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Anthera Pharmaceuticals, Inc.. Trailing twelve-month EPS for Anthera Pharmaceuticals, Inc. stands at -$1.65. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Anthera Pharmaceuticals, Inc.. Anthera Pharmaceuticals, Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Anthera Pharmaceuticals, Inc. valued side by side against its closest peers. Anthera Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Anthera Pharmaceuticals, Inc., and how their positions are changing. At a $2,618 market value, institutional positions materially move Anthera Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Anthera Pharmaceuticals, Inc. executives and directors. Shares of Anthera Pharmaceuticals, Inc. have traded between $0.0001 and $0.0010 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Anthera Pharmaceuticals, Inc.. Anthera Pharmaceuticals, Inc. is a $2,618 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Anthera Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Anthera Pharmaceuticals, Inc.. Coverage tracks Anthera Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.